Watch TCRT. Know when insiders buy.
One email the day a filing lands. Free.
TCRT
Alaunos Therapeutics, Inc.
1.02
−0.07 −6.37%
USD · close Sep 28
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
100
PASS · shorts 100
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $2.6MP/E —DIV YIELD —FCF YIELD —REV TTM $3K −50.0%NET INCOME −$4MNET CASH $124K52W 1.02 – 4.36SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $0 | — | — | −$952K | −$952K | — | -0.41 | −$300K | — | — | Aug 14 |
| Q1 2026 · Mar 31 | $0 | −100.0% | — | −$1M | −$1M | — | -0.59 | −$1M | — | — | May 15 |
| Q4 2025 · Dec 31derived | $3K | −25.0% | — | −$907K | −$893K | — | -0.36 | −$552K | $1K | −$553K | Mar 31 |
| Q3 2025 · Sep 30 | $0 | — | — | −$1.2M | −$1.2M | — | -0.55 | −$844K | — | — | Nov 14 |
| Q2 2025 · Jun 30 | $0 | −100.0% | — | −$1M | −$1.1M | — | -0.63 | −$701K | — | — | Aug 14 |
| Q1 2025 · Mar 31 | $2K | +100.0% | — | −$1.1M | −$1.1M | — | -0.67 | −$772K | — | — | May 15 |
| Q4 2024 · Dec 31derived | $4K | +300.0% | — | −$755K | −$742K | −103.3% | -0.46 | −$592K | $0 | −$592K | Mar 31 |
| Q3 2024 · Sep 30 | $0 | — | — | −$1.1M | −$1.1M | — | -0.70 | −$781K | $0 | −$781K | Nov 14 |
| Q2 2024 · Jun 30 | $4K | — | — | −$1.2M | −$1.1M | — | -0.71 | −$1.7M | $0 | −$1.7M | Aug 14 |
| Q1 2024 · Mar 31 | $1K | — | — | −$1.7M | −$1.7M | — | -1.05 | −$1.9M | $0 | −$1.9M | May 15 |
| Q4 2023 · Dec 31derived | $1K | — | — | −$7.9M | $22.6M | — | -4.90 | −$7.4M | $0 | −$7.4M | Mar 31 |
| Q3 2023 · Sep 30 | $0 | — | — | −$8.7M | −$8.5M | — | -5.30 | −$6.4M | $1K | −$6.4M | Nov 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $5K | — | −$4.2M | −$4.2M | -83520.0% | -2.20 | −$2.9M | $98K | −$3M | — | — |
| FY2024 · to Dec 31 | $10K | — | −$4.8M | −$4.7M | -46790.0% | -2.92 | −$5M | $0 | −$5M | — | — |
| FY2023 · to Dec 31 | $5K | — | −$34.3M | −$4.7M | -93580.0% | -21.97 | −$30.1M | $197K | −$30.3M | $0 | — |
| FY2022 · to Dec 31 | $2.9M | — | −$35.1M | −$37.7M | -1291.2% | -2.61 | −$29.2M | $216K | −$29.4M | $45K | — |
| FY2021 · to Dec 31 | $398K | — | −$77.5M | −$78.8M | -19786.7% | -0.37 | −$61.5M | $3.3M | −$64.8M | $0 | — |
| FY2020 · to Dec 31 | $0 | — | −$80.4M | −$80M | — | -0.38 | −$57M | $9.8M | −$66.8M | — | — |
Every number comes from Alaunos Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.